Labcorp (LH)
Market Price (6/20/2026): $255.905 | Market Cap: $21.1 BilInvestor Relations Sector: Health Care | Industry: Health Care Services
Labcorp (LH)
Market Price (6/20/2026): $255.905Market Cap: $21.1 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.6%, FCF Yield is 6.6% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% Stock buyback supportStock Buyback 3Y Total is 1.7 Bil Low stock price volatilityVol 12M is 23% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -4.9%, 3Y Excs Rtn is -57% | Key risksLH key risks include [1] persistently slow organic growth and declining operating margins. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.6%, FCF Yield is 6.6% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Stock buyback supportStock Buyback 3Y Total is 1.7 Bil |
| Low stock price volatilityVol 12M is 23% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -4.9%, 3Y Excs Rtn is -57% |
| Key risksLH key risks include [1] persistently slow organic growth and declining operating margins. |
Qualitative Assessment
AI Analysis | Feedback
Labcorp (LH) stock has lost about 10% since 2/28/2026 because of the following key factors:
1. Muted Investor Reaction to Q1 2026 Earnings Despite Beat.
Labcorp reported strong first-quarter 2026 financial results on April 30, 2026, exceeding analyst expectations with adjusted earnings per share (EPS) of $4.25 against a consensus of $4.09, and revenue of $3.54 billion surpassing the $3.51 billion forecast. The company also raised its full-year 2026 adjusted EPS guidance to a midpoint of $18.03, an increase of $0.13 from previous guidance, implying approximately 10% growth. Despite these positive results and raised guidance, the stock experienced a muted or slightly negative market reaction on the day of the announcement, closing with a minor pre-market decline of 0.51%. This "sell the news" reaction suggested that the market had largely priced in the expected performance, and the guidance, while increased, was only modestly above prior consensus, leading to limited incremental upside perceived by investors.
2. Persistent Concerns Regarding PAMA Reimbursement Pressure.
Ongoing uncertainty and future financial pressure from the Protecting Access to Medicare Act (PAMA) likely weighed on investor sentiment. While Medicare payment cuts of up to 15% were delayed through December 31, 2026, the upcoming PAMA reporting cycle (May 1 to July 31, 2026) will dictate future Clinical Laboratory Fee Schedule (CLFS) rates, with potential annual reductions of up to 15% from 2027 to 2029. Labcorp had previously stated an expected $100 million impact to both its top and bottom lines in 2026 if these cuts were not further delayed, anticipating only being able to offset roughly $25 million of this impact. This long-term reimbursement risk contributes to a cautious outlook for diagnostic service providers like Labcorp.
Show more
Labcorp (LH) stock has lost about 10% since 2/28/2026 because of the following key factors:
1. Muted Investor Reaction to Q1 2026 Earnings Despite Beat.
Labcorp reported strong first-quarter 2026 financial results on April 30, 2026, exceeding analyst expectations with adjusted earnings per share (EPS) of $4.25 against a consensus of $4.09, and revenue of $3.54 billion surpassing the $3.51 billion forecast. The company also raised its full-year 2026 adjusted EPS guidance to a midpoint of $18.03, an increase of $0.13 from previous guidance, implying approximately 10% growth. Despite these positive results and raised guidance, the stock experienced a muted or slightly negative market reaction on the day of the announcement, closing with a minor pre-market decline of 0.51%. This "sell the news" reaction suggested that the market had largely priced in the expected performance, and the guidance, while increased, was only modestly above prior consensus, leading to limited incremental upside perceived by investors.
2. Persistent Concerns Regarding PAMA Reimbursement Pressure.
Ongoing uncertainty and future financial pressure from the Protecting Access to Medicare Act (PAMA) likely weighed on investor sentiment. While Medicare payment cuts of up to 15% were delayed through December 31, 2026, the upcoming PAMA reporting cycle (May 1 to July 31, 2026) will dictate future Clinical Laboratory Fee Schedule (CLFS) rates, with potential annual reductions of up to 15% from 2027 to 2029. Labcorp had previously stated an expected $100 million impact to both its top and bottom lines in 2026 if these cuts were not further delayed, anticipating only being able to offset roughly $25 million of this impact. This long-term reimbursement risk contributes to a cautious outlook for diagnostic service providers like Labcorp.
3. Weaker-Than-Anticipated Organic Volume Growth in Diagnostics.
In Q1 2026, Labcorp's Diagnostics Laboratories segment reported a 5.0% year-over-year revenue increase, reaching $2.76 billion. However, organic diagnostic revenue growth was only 3%, with acquisitions contributing an additional 2%. Furthermore, total requisitions showed a modest increase of 4.9% but fell short of the anticipated 5.2% growth. This suggests that while acquisitions provided a boost, the company's core organic testing volume growth was less robust than market expectations, signaling potential underlying weaknesses in demand beyond inorganic growth strategies.
Show less
Stock Movement Drivers
Fundamental Drivers
The -11.3% change in LH stock from 2/28/2026 to 6/19/2026 was primarily driven by a -17.7% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 288.33 | 255.82 | -11.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13,952 | 14,144 | 1.4% |
| Net Income Margin (%) | 6.3% | 6.7% | 6.0% |
| P/E Multiple | 27.2 | 22.4 | -17.7% |
| Shares Outstanding (Mil) | 83 | 82 | 0.4% |
| Cumulative Contribution | -11.3% |
Market Drivers
2/28/2026 to 6/19/2026| Return | Correlation | |
|---|---|---|
| LH | -11.3% | |
| Market (SPY) | 9.2% | 31.0% |
| Sector (XLV) | -6.4% | 57.5% |
Fundamental Drivers
The -4.3% change in LH stock from 11/30/2025 to 6/19/2026 was primarily driven by a -13.9% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 267.37 | 255.82 | -4.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13,765 | 14,144 | 2.8% |
| Net Income Margin (%) | 6.2% | 6.7% | 7.1% |
| P/E Multiple | 26.0 | 22.4 | -13.9% |
| Shares Outstanding (Mil) | 83 | 82 | 1.0% |
| Cumulative Contribution | -4.3% |
Market Drivers
11/30/2025 to 6/19/2026| Return | Correlation | |
|---|---|---|
| LH | -4.3% | |
| Market (SPY) | 9.9% | 19.4% |
| Sector (XLV) | -4.4% | 42.4% |
Fundamental Drivers
The 3.8% change in LH stock from 5/31/2025 to 6/19/2026 was primarily driven by a 20.0% change in the company's Net Income Margin (%).| (LTM values as of) | 5312025 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 246.37 | 255.82 | 3.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13,177 | 14,144 | 7.3% |
| Net Income Margin (%) | 5.5% | 6.7% | 20.0% |
| P/E Multiple | 28.2 | 22.4 | -20.7% |
| Shares Outstanding (Mil) | 84 | 82 | 1.6% |
| Cumulative Contribution | 3.8% |
Market Drivers
5/31/2025 to 6/19/2026| Return | Correlation | |
|---|---|---|
| LH | 3.8% | |
| Market (SPY) | 28.1% | 18.3% |
| Sector (XLV) | 14.6% | 39.7% |
Fundamental Drivers
The 23.5% change in LH stock from 5/31/2023 to 6/19/2026 was primarily driven by a 22.2% change in the company's P/E Multiple.| (LTM values as of) | 5312023 | 6192026 | Change |
|---|---|---|---|
| Stock Price ($) | 207.06 | 255.82 | 23.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11,757 | 14,144 | 20.3% |
| Net Income Margin (%) | 8.5% | 6.7% | -21.8% |
| P/E Multiple | 18.3 | 22.4 | 22.2% |
| Shares Outstanding (Mil) | 88 | 82 | 7.4% |
| Cumulative Contribution | 23.5% |
Market Drivers
5/31/2023 to 6/19/2026| Return | Correlation | |
|---|---|---|
| LH | 23.5% | |
| Market (SPY) | 85.7% | 33.5% |
| Sector (XLV) | 22.9% | 48.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LH Return | 54% | -25% | -3% | 2% | 11% | 4% | 31% |
| Peers Return | 47% | -15% | 9% | 2% | 25% | -15% | 47% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| LH Win Rate | 83% | 33% | 33% | 50% | 67% | 50% | |
| Peers Win Rate | 70% | 47% | 53% | 47% | 57% | 43% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| LH Max Drawdown | -12% | -35% | -23% | -17% | -17% | -13% | |
| Peers Max Drawdown | -15% | -33% | -25% | -21% | -23% | -30% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DGX, IQV, TMO, ABT, MEDP. See LH Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | LH | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -14.1% | -18.8% |
| % Gain to Breakeven | 16.4% | 23.1% |
| Time to Breakeven | 11 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -10.8% | -9.5% |
| % Gain to Breakeven | 12.1% | 10.5% |
| Time to Breakeven | 40 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -16.1% | -6.7% |
| % Gain to Breakeven | 19.1% | 7.1% |
| Time to Breakeven | 567 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.1% | -33.7% |
| % Gain to Breakeven | 82.0% | 50.9% |
| Time to Breakeven | 115 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -29.7% | -19.2% |
| % Gain to Breakeven | 42.2% | 23.8% |
| Time to Breakeven | 186 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -11.1% | -3.7% |
| % Gain to Breakeven | 12.5% | 3.9% |
| Time to Breakeven | 92 days | 6 days |
In The Past
Labcorp's stock fell -14.1% during the 2025 US Tariff Shock. Such a loss loss requires a 16.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LH | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -45.1% | -33.7% |
| % Gain to Breakeven | 82.0% | 50.9% |
| Time to Breakeven | 115 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -29.7% | -19.2% |
| % Gain to Breakeven | 42.2% | 23.8% |
| Time to Breakeven | 186 days | 105 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -30.2% | -53.4% |
| % Gain to Breakeven | 43.3% | 114.4% |
| Time to Breakeven | 311 days | 1085 days |
In The Past
Labcorp's stock fell -14.1% during the 2025 US Tariff Shock. Such a loss loss requires a 16.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Labcorp (LH)
Labcorp (LH) is a global independent clinical laboratory company operating through two main segments: Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Essentially, the company provides a wide array of medical testing services and also offers comprehensive solutions for the development of new drugs, medical devices, and diagnostics.
The Labcorp Diagnostics segment provides an extensive range of medical tests, from routine blood work, urinalyses, and STD screenings to highly specialized gene-based and esoteric testing for complex diseases like cancer, cardiovascular conditions, and infectious diseases. This segment also includes occupational testing, medical drug monitoring, and online applications for patients to access results and for managed care organizations.
The Labcorp Drug Development segment offers end-to-end solutions for pharmaceutical and biotechnology companies, spanning from early-stage research to clinical trials and commercial market access. Labcorp's diverse customer base includes managed care organizations, biopharmaceutical companies, physicians, hospitals, governmental agencies, employers, and directly serves patients and consumers globally.
AI Analysis | Feedback
Here are 1-3 brief analogies for Labcorp:
It's like the Amazon Web Services (AWS) of the healthcare industry, providing crucial infrastructure and support for everything from patient diagnostics to pharmaceutical research and development.
Think of them as a combination of Underwriters Laboratories (UL), rigorously testing and providing vital information about human health, and a specialized Accenture for pharmaceutical research and development services.
AI Analysis | Feedback
- Clinical Laboratory Testing: Provides a comprehensive suite of routine and specialized diagnostic tests for various health conditions.
- Specialty and Advanced Diagnostics: Offers highly specialized and esoteric testing, including gene-based, disease-specific, and genetic analyses.
- Occupational and Wellness Testing: Delivers services such as medical drug monitoring, chronic disease programs, and kidney stone prevention tests for employers and individuals.
- Drug Development Services: Offers end-to-end solutions supporting biopharmaceutical companies from early research through clinical trials and commercialization.
- Medical Device and Diagnostic Development Services: Provides comprehensive development support for new medical devices and diagnostic tools.
AI Analysis | Feedback
Labcorp (LH) primarily sells its services to other companies and organizations. While specific names of individual customer companies are not provided in the background information, the major categories of organizations it serves are:
- Healthcare Providers and Systems: This includes physicians, hospitals, health systems, and other healthcare providers who utilize Labcorp's diagnostic services for their patients. It also includes independent clinical laboratories that may outsource specialized tests.
- Managed Care Organizations: These are health insurance companies and similar entities that contract with Labcorp for diagnostic services for their members.
- Biopharmaceutical and Research Companies: This category encompasses biopharmaceutical companies, contract research organizations (CROs), crop protection and chemical companies, and academic institutions that leverage Labcorp's end-to-end drug development, medical device, and diagnostic development solutions.
- Governmental Agencies and Employers: These entities contract with Labcorp for various services, including occupational testing, chronic disease programs, and support for drug development and public health initiatives.
AI Analysis | Feedback
AI Analysis | Feedback
Adam H. Schechter became Chief Executive Officer of Labcorp in November 2019 and Chairman of the Board in May 2020. He had a long and distinguished career at Merck & Co., Inc. for 31 years, where he started as a sales representative in 1988. His roles at Merck included Executive Vice President and President of Global Human Health from 2010 to 2018, leading the company's worldwide pharmaceutical and vaccine businesses. During his tenure at Merck, he led the integration of Merck and Schering-Plough and transformed Merck's commercial model.
Julia A. Wang, Executive Vice President and Chief Financial OfficerJulia A. Wang joined Labcorp as Executive Vice President and Chief Financial Officer in December 2024. Prior to Labcorp, she served as CFO of BeiGene from June 2021 to July 2024, where she was instrumental in driving business transformations and accelerating growth. Her previous experience includes senior finance leadership roles at Alexion Pharmaceuticals, Quest Diagnostics, Johnson & Johnson (as CFO of various operating businesses in medical devices and pharmaceuticals), and PepsiCo.
Megan D. Bailey, Executive Vice President and President, Central Laboratories and InternationalMegan D. Bailey has served as Labcorp's Executive Vice President and President, Central Laboratories and International since September 2024. She previously held the roles of Labcorp's Executive Vice President and Chief Strategy and Transformation Officer, and Chief of Staff to the CEO. Bailey joined Labcorp through its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company, where she served as Chief Executive Officer and a member of the board of directors. As CEO of PGDx, she led the company through growth, financing, product development, regulatory approvals, and its eventual sale to Labcorp. Before PGDx, she spent more than 10 years at Roche Diagnostics in various commercial leadership roles.
Mark Schroeder, Executive Vice President and President, Diagnostics and Chief Operations OfficerMark Schroeder has served as Labcorp's Executive Vice President and President, Diagnostics and Chief Operations Officer since 2023. He joined Labcorp in 2007 and has held numerous senior leadership positions in laboratory and supply chain operations, including leading the West Division and the Integrated Genetics, Oncology, and Dianon Pathology businesses. Schroeder was instrumental in expanding the company's laboratory capabilities in response to the COVID-19 pandemic and has been an integral architect of process improvement initiatives for Labcorp. Prior to joining Labcorp, he was the Senior Vice President of Sales, Operations, and Business Development at DSC Logistics.
AI Analysis | Feedback
The key risks to Labcorp's business (LH) primarily stem from regulatory pressures, intense market competition, and vulnerabilities related to data privacy and cybersecurity.
- Regulatory and Reimbursement Changes: Labcorp faces significant financial risks due to evolving healthcare regulations and reimbursement policies, particularly under the Protecting Access to Medicare Act (PAMA). These changes can lead to substantial reductions in reimbursement rates for laboratory services, directly impacting the company's revenue and profitability. For instance, a potential $100 million annual impact from PAMA reimbursement cuts is anticipated in 2026.
- Intense Competition and Market Dynamics: Both the clinical laboratory diagnostics and drug development segments in which Labcorp operates are highly competitive. The company must continuously innovate and deliver high-quality services to maintain its market share against numerous competitors, ranging from smaller providers to large global enterprises. Price sensitivity, the emergence of alternative testing methods, and challenges with organic sales growth and margin pressure further exacerbate this risk.
- Data Privacy, Cybersecurity, and Third-Party Vendor Risks: As a major handler of sensitive patient data, Labcorp is exposed to considerable risks related to data breaches and cybersecurity threats, particularly those originating from third-party vendors. The company has previously experienced data breaches through third-party collection firms, resulting in the exposure of millions of consumers' personal and financial information. Such incidents can lead to significant reputational damage, legal liabilities, and financial losses.
AI Analysis | Feedback
The emergence of advanced point-of-care (POC) testing technologies and direct-to-consumer/at-home diagnostic kits poses a clear emerging threat. These innovations allow for increasingly complex and accurate diagnostic tests to be performed outside of traditional centralized laboratories, either in a physician's office or by patients themselves at home. This shift could reduce the volume of samples sent to large clinical laboratories like Labcorp, as it offers greater convenience, faster results, and potentially lower costs to patients and healthcare providers, thereby disintermediating Labcorp's core diagnostics business model.
AI Analysis | Feedback
Labcorp (symbol: LH) operates in two main segments: Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Both segments address substantial and growing markets globally and within the U.S.
Labcorp Diagnostics (Dx)
The Labcorp Diagnostics segment, which provides a wide array of clinical laboratory testing services, participates in the broader diagnostic testing and clinical laboratory services markets.
- Global Diagnostic Testing Market: The global diagnostic testing market size was estimated at USD 207.96 billion in 2025 and is forecasted to reach nearly USD 272.98 billion by 2034. Another estimate values the global clinical laboratory services market size at USD 319.13 billion in 2024, with projections to reach USD 569.17 billion by 2032.
- U.S. Diagnostic Testing Market: The United States diagnostics market was valued at USD 85.63 billion in 2025 and is expected to grow to USD 186.59 billion by 2035. Similarly, the U.S. clinical laboratory services market was valued at US$ 99.7 billion in 2024 and is projected to reach US$ 144.3 billion by 2033.
Labcorp Drug Development (DD)
The Labcorp Drug Development segment offers end-to-end drug, medical device, and diagnostic development solutions, operating within the contract research organization (CRO) services market.
- Global Contract Research Organization (CRO) Services Market: The global contract research organization (CRO) services market size was valued at USD 92.27 billion in 2025, with projections to grow to USD 199.28 billion by 2034. Another report estimates the global CRO market to reach US$ 113.79 billion by 2031, from US$ 65.39 billion in 2024.
- U.S. Contract Research Organization (CRO) Services Market: The U.S. contract research organization (CRO) services market size was valued at USD 32.99 billion in 2022. It is also estimated to be valued at USD 21.85 billion in 2025 and is expected to reach USD 49.56 billion by 2032.
AI Analysis | Feedback
- Organic Growth Across Diagnostics and Central Laboratory Services: Labcorp anticipates continued robust organic growth within its Diagnostics and Central Laboratory segments. The company reported strong organic growth of 4.1% in Diagnostics and 7.7% (constant currency) in Central Lab for the fourth quarter of 2025, driven by healthy utilization and its significant market presence. Management expects this underlying business performance to continue contributing to revenue expansion.
- Strategic Acquisitions and Partnerships: Labcorp actively pursues tuck-in acquisitions and fosters partnerships to expand its service offerings and geographic reach. In 2025, the company expanded partnerships with health systems and regional/local laboratories, signing or closing 13 transactions. Completed acquisitions included select outreach laboratory services from various health systems and anatomic pathology assets, which are aimed at broadening access to its routine and specialty tests and enhancing operational efficiencies.
- Expansion of Specialty Testing Offerings and Innovation: Labcorp is committed to innovation and the continuous launch of new specialty testing services. In 2025, the company introduced over 130 innovative new tests, focusing on high-growth therapeutic areas such as oncology, women's health, neurology, and autoimmune diseases. Recent additions also include tests for lead exposure, ApoB for heart health, and a healthy aging panel, indicating a strategy to diversify and enhance its advanced testing menu.
- Investment in Infrastructure and Technology, Including AI: To support future growth and efficiency, Labcorp is making significant investments in its infrastructure and technological capabilities. This includes a strategic investment to construct a modern, state-of-the-art 500,000-plus square foot Central Laboratory and kit production facility, with construction expected to commence in 2026. The company is also making significant investments in artificial intelligence (AI) to optimize operations and enhance service delivery.
AI Analysis | Feedback
Share Repurchases
- Labcorp completed a share repurchase program announced in December 2021, buying back 15,206,645 shares for $3,640.51 million by Q4 2025.
- In Q4 2025, the company repurchased $225 million of common stock, contributing to a total of $450 million in share repurchases for the full year 2025.
- As of February 2026, Labcorp had approximately $800 million of share repurchase authorization remaining.
Outbound Investments
- Labcorp completed the acquisition of select assets of BioReference Health's oncology and related clinical testing services businesses for up to $225 million in September 2025.
- In 2025, Labcorp invested $582.0 million in acquisitions.
- Other acquisitions and strategic agreements in 2025 included assets from Invitae (for specialty testing in oncology and rare diseases) and select ambulatory outreach laboratory assets from Community Health Systems for approximately $194 million.
Capital Expenditures
- Labcorp's capital expenditures were $123.9 million in Q4 2025.
- For 2026, capital expenditures are expected to be approximately 4% of revenue.
- A primary focus of planned capital expenditures for 2026 is the investment in a new state-of-the-art 500,000-plus square foot central laboratory and kit production facility to support long-term growth.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Labcorp Stock In Shambles: Down 7.5% With 9-Day Losing Streak | 05/05/2026 | |
| Labcorp Stock Slides 6.4% With A 8-Day Losing Spree | 05/02/2026 | |
| Labcorp Earnings Notes | 12/29/2026 | |
| How Low Can Labcorp Stock Really Go? | 10/17/2025 | |
| Labcorp vs Alphabet: Which Is A Better Investment? | 08/18/2025 | |
| Labcorp vs HCA Healthcare: Which Is A Better Investment? | 08/18/2025 | |
| Labcorp vs Quest Diagnostics: Which Is A Better Investment? | 08/18/2025 | |
| How Does Labcorp Stock Stack Up Against Its Peers? | 08/13/2025 | |
| ARTICLES | ||
| 9-Day Sell-Off Sends Labcorp Stock Down -7.5% | 05/05/2026 | |
| Labcorp Stock 8-Day Losing Spree: Stock Falls -6.4% | 05/02/2026 | |
| Mid Cap Stocks Trading At 52-Week High | 09/27/2025 | |
| S&P 500 Stocks Trading At 52-Week High | 08/21/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 225.41 |
| Mkt Cap | 24.9 |
| Rev LTM | 15,388 |
| Op Inc LTM | 1,970 |
| FCF LTM | 1,750 |
| FCF 3Y Avg | 1,539 |
| CFO LTM | 2,277 |
| CFO 3Y Avg | 2,066 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 5.2% |
| Rev Chg Q | 8.1% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 11.8% |
| Op Inc Chg 3Y Avg | 7.0% |
| Op Mgn LTM | 15.7% |
| Op Mgn 3Y Avg | 15.4% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 17.4% |
| CFO/Rev 3Y Avg | 17.9% |
| FCF/Rev LTM | 13.8% |
| FCF/Rev 3Y Avg | 13.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 24.9 |
| P/S | 2.7 |
| P/Op Inc | 16.7 |
| P/EBIT | 16.5 |
| P/E | 23.5 |
| P/CFO | 13.9 |
| Total Yield | 5.3% |
| Dividend Yield | 0.6% |
| FCF Yield 3Y Avg | 5.1% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.3% |
| 3M Rtn | -0.8% |
| 6M Rtn | -18.5% |
| 12M Rtn | 9.5% |
| 3Y Rtn | 1.2% |
| 1M Excs Rtn | -0.2% |
| 3M Excs Rtn | -14.2% |
| 6M Excs Rtn | -28.3% |
| 12M Excs Rtn | -15.5% |
| 3Y Excs Rtn | -68.3% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostics Laboratories (Dx) | 10,876 | 10,144 | 9,415 | 9,204 | 10,364 |
| Biopharma Laboratory Services (BLS) | 3,098 | 2,923 | 2,774 | 2,697 | 5,846 |
| Intercompany eliminations and other | -23 | -58 | -28 | -37 | -88 |
| Total | 13,952 | 13,009 | 12,162 | 11,864 | 16,121 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostics Laboratories (Dx) | 1,780 | 1,606 | 1,591 | 2,026 | 3,206 |
| Biopharma Laboratory Services (BLS) | 498 | 459 | 396 | 389 | 887 |
| Goodwill and other asset impairments | -4 | -5 | -349 | -262 | |
| Restructuring and other charges | -127 | -46 | -49 | -54 | -43 |
| Amortization of intangibles and other assets | -280 | -256 | -220 | -194 | -370 |
| General corporate and unallocated expenses | -482 | -671 | -644 | -469 | -420 |
| Total | 1,385 | 1,087 | 726 | 1,436 | 3,260 |
Price Behavior
| Market Price | $255.82 | |
| Market Cap ($ Bil) | 21.1 | |
| First Trading Date | 03/29/1990 | |
| Distance from 52W High | -11.4% | |
| 50 Days | 200 Days | |
| DMA Price | $260.66 | $266.18 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -1.9% | -3.9% |
| 3M | 1YR | |
| Volatility | 21.7% | 23.1% |
| Downside Capture | 42.29 | 35.43 |
| Upside Capture | 13.97 | 24.40 |
| Correlation (SPY) | 20.8% | 17.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.47 | 0.88 | 0.73 | 0.47 | 0.42 | 0.53 |
| Up Beta | 0.39 | 1.03 | 0.80 | 0.61 | 0.54 | 0.64 |
| Down Beta | 2.13 | 0.24 | 0.47 | 0.68 | 0.38 | 0.49 |
| Up Capture | 19% | 31% | 36% | 22% | 27% | 18% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 16 | 25 | 58 | 128 | 391 |
| Down Capture | 0% | 189% | 121% | 47% | 50% | 74% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 12 | 25 | 38 | 65 | 121 | 358 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LH | |
|---|---|---|---|---|
| LH | -0.4% | 23.0% | -0.08 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 39.0% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 17.0% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 15.6% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -9.7% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 44.6% |
| Bitcoin (BTCUSD) | -40.0% | 42.5% | -1.08 | -2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LH | |
|---|---|---|---|---|
| LH | 0.9% | 24.2% | 0.01 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 54.8% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 43.7% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 9.8% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | 5.1% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 49.2% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | 14.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LH | |
|---|---|---|---|---|
| LH | 7.5% | 27.0% | 0.30 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 60.6% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 55.5% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 9.4% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 14.3% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 54.9% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -0.1% | -0.1% | 1.4% |
| 2/17/2026 | -2.1% | 0.9% | -4.0% |
| 10/28/2025 | -5.8% | -6.5% | -2.1% |
| 7/24/2025 | 6.9% | 5.3% | 10.4% |
| 4/29/2025 | 4.7% | 7.5% | 7.6% |
| 2/6/2025 | -0.9% | -3.5% | 1.5% |
| 10/24/2024 | 4.6% | 4.8% | 9.2% |
| 8/1/2024 | 8.3% | 1.8% | 6.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 13 | 12 |
| # Negative | 11 | 11 | 12 |
| Median Positive | 3.5% | 3.2% | 5.7% |
| Median Negative | -2.6% | -2.6% | -5.1% |
| Max Positive | 8.3% | 7.5% | 10.4% |
| Max Negative | -5.9% | -6.5% | -14.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -0.1% | -0.1% | 1.4% |
| 2/17/2026 | -2.1% | 0.9% | -4.0% |
| 10/28/2025 | -5.8% | -6.5% | -2.1% |
| 7/24/2025 | 6.9% | 5.3% | 10.4% |
| 4/29/2025 | 4.7% | 7.5% | 7.6% |
| 2/6/2025 | -0.9% | -3.5% | 1.5% |
| 10/24/2024 | 4.6% | 4.8% | 9.2% |
| 8/1/2024 | 8.3% | 1.8% | 6.9% |
| 4/25/2024 | -4.6% | -3.2% | -5.2% |
| 2/15/2024 | -2.6% | -4.5% | -8.3% |
| 10/26/2023 | 4.2% | 3.2% | 7.6% |
| 7/27/2023 | -1.3% | -1.8% | -2.9% |
| 4/25/2023 | -4.8% | -1.2% | -5.9% |
| 2/16/2023 | 3.2% | -1.3% | -14.1% |
| 10/27/2022 | -5.9% | -2.3% | 5.0% |
| 7/28/2022 | 1.2% | 1.3% | -5.0% |
| 4/28/2022 | -4.9% | 0.3% | -1.1% |
| 2/10/2022 | 0.2% | -4.3% | -5.7% |
| 10/28/2021 | 1.7% | 2.5% | 3.1% |
| 7/29/2021 | 4.1% | 6.0% | 6.5% |
| 4/29/2021 | 1.6% | 5.1% | 4.8% |
| 2/11/2021 | 3.5% | 5.9% | 4.1% |
| 10/27/2020 | 2.2% | 2.6% | -1.6% |
| 7/28/2020 | -2.4% | -2.6% | -10.8% |
| SUMMARY STATS | |||
| # Positive | 13 | 13 | 12 |
| # Negative | 11 | 11 | 12 |
| Median Positive | 3.5% | 3.2% | 5.7% |
| Median Negative | -2.6% | -2.6% | -5.1% |
| Max Positive | 8.3% | 7.5% | 10.4% |
| Max Negative | -5.9% | -6.5% | -14.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/04/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/31/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 10/29/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/26/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/01/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/04/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 10/31/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 10/29/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/26/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/01/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/04/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 10/29/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/28/2020 | 10-K |
| 09/30/2019 | 10/31/2019 | 10-Q |
| 06/30/2019 | 08/08/2019 | 10-Q |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 14.65 Bil | 14.72 Bil | 14.80 Bil | 0.2% | Raised | Guidance: 14.70 Bil for 2026 | |
| 2026 Revenue Growth | 5.0% | 5.55% | 6.1% | ||||
| 2026 Adjusted EPS | 17.7 | 18 | 18.4 | 0.7% | Raised | Guidance: 17.9 for 2026 | |
| 2026 Free Cash Flow | 1.24 Bil | 1.30 Bil | 1.36 Bil | 0 | Affirmed | Guidance: 1.30 Bil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 14.61 Bil | 14.70 Bil | 14.79 Bil | 5.4% | Raised | Guidance: 13.95 Bil for 2025 | |
| 2026 Adjusted EPS | 17.6 | 17.9 | 18.2 | 8.9% | Raised | Guidance: 16.3 for 2025 | |
| 2026 Free Cash Flow | 1.24 Bil | 1.30 Bil | 1.36 Bil | 5.7% | Raised | Guidance: 1.23 Bil for 2025 | |
Insider Activity
Updated 6/10/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kyle, Kathryn W | EVP, Chief Legal Officer | Direct | Sell | 6102026 | 263.89 | 762 | 201,084 | 1,006,333 | Form |
| 2 | Schechter, Adam H | President & CEO | Direct | Sell | 5132026 | 254.50 | 5,903 | 1,502,314 | 27,291,053 | Form |
| 3 | Wilkinson, Peter J | SVP, Chief Accounting Officer | Direct | Sell | 3302026 | 267.05 | 1,633 | 436,093 | 494,635 | Form |
| 4 | Meltzer, Jonathan C | EVP, Operations | Direct | Sell | 3302026 | 267.05 | 839 | 224,055 | 966,808 | Form |
| 5 | Schechter, Adam H | President & CEO | Direct | Sell | 3052026 | 279.96 | 8,705 | 2,437,047 | 22,613,169 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kyle, Kathryn W | EVP, Chief Legal Officer | Direct | Sell | 6102026 | 263.89 | 762 | 201,084 | 1,006,333 | Form |
| 2 | Schechter, Adam H | President & CEO | Direct | Sell | 5132026 | 254.50 | 5,903 | 1,502,314 | 27,291,053 | Form |
| 3 | Wilkinson, Peter J | SVP, Chief Accounting Officer | Direct | Sell | 3302026 | 267.05 | 1,633 | 436,093 | 494,635 | Form |
| 4 | Meltzer, Jonathan C | EVP, Operations | Direct | Sell | 3302026 | 267.05 | 839 | 224,055 | 966,808 | Form |
| 5 | Schechter, Adam H | President & CEO | Direct | Sell | 3052026 | 279.96 | 8,705 | 2,437,047 | 22,613,169 | Form |
| 6 | Van, Der Vaart Sandra D | EVP, Corporate Affairs | Direct | Sell | 3032026 | 284.91 | 548 | 156,000 | 734,768 | Form |
| 7 | Caveney, Brian J | EVP, Pres of ED, CMO & CSO | Direct | Sell | 2262026 | 286.31 | 1,500 | 429,458 | 8,619,763 | Form |
| 8 | Wilkinson, Peter J | SVP, Chief Accounting Officer | Direct | Sell | 2232026 | 277.94 | 666 | 185,108 | 514,806 | Form |
| 9 | Meltzer, Jonathan C | EVP, Operations | Direct | Sell | 2122026 | 276.79 | 91 | 25,188 | 746,316 | Form |
| 10 | Meltzer, Jonathan C | EVP, Operations | Direct | Sell | 2102026 | 275.53 | 88 | 24,247 | 790,585 | Form |
| 11 | Schechter, Adam H | President & CEO | Direct | Sell | 11132025 | 262.75 | 5,745 | 1,509,499 | 23,010,068 | Form |
| 12 | Parham, Richelle P | Direct | Sell | 11042025 | 254.28 | 7,009 | 1,782,273 | 627,826 | Form | |
| 13 | Van, Der Vaart Sandra D | EVP, Chief Legal Officer | Direct | Sell | 8152025 | 271.42 | 3,903 | 1,059,371 | 617,130 | Form |
| 14 | Schechter, Adam H | President & CEO | Direct | Sell | 8132025 | 266.78 | 5,643 | 1,505,440 | 24,895,643 | Form |
| 15 | Gilliland, Dwight Gary | Direct | Sell | 8012025 | 264.95 | 2,000 | 529,900 | 1,763,507 | Form | |
| 16 | Wilkinson, Peter J | SVP, Chief Accounting Officer | Direct | Sell | 7312025 | 261.02 | 202 | 52,727 | 483,471 | Form |
| 17 | Anderson, Kerrii B | Direct | Sell | 7282025 | 280.00 | 3,500 | 980,000 | 2,426,480 | Form | |
| 18 | Anderson, Kerrii B | Direct | Sell | 7282025 | 280.00 | 3,500 | 980,000 | 2,426,480 | Form | |
| 19 | Anderson, Kerrii B | Direct | Sell | 7022025 | 265.00 | 500 | 132,500 | 3,223,990 | Form | |
| 20 | Anderson, Kerrii B | Direct | Sell | 6122025 | 260.00 | 500 | 130,000 | 3,293,160 | Form | |
| 21 | Caveney, Brian J | EVP, Pres of ED, CMO & CSO | Direct | Sell | 6052025 | 247.00 | 2,000 | 494,000 | 7,426,464 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.